In the syngeneic CT26 CRC model in immuno-competent Balb/c mice, lucicebtide (25 or 50 mg/kg) resulted in 49.3% and 66.7% TGI (1-way ANOVA of *p<0.05 and **p<0.01; n=5 mice/group; Supplementary Figure S7A). This evidence concerns the gene DDX53 and colorectal carcinoma.